Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers

Oncology Reports

Volumn 30, Issue 1, 2013, Pages 413-418

  Seitz, S ^a,b,c   Rick, F G ^b   Schally, A V ^b,c   Treszl, A ^b,c   Hohla, F ^b,c,d   Szalontay, L ^b   Zarandi, M ^b,c   Ortmann, O ^a   Engel, J B ^a   Buchholz, S ^a,b,c  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF SALZBURG   (Austria)

Author keywords

Growth hormone releasing hormone antagonist; Splice variant 1; Triple negative breast cancer

Indexed keywords

ANGIOPOIETIN 1; CASPASE 14; CASPASE 4; CASPASE 5; CD70 ANTIGEN; DOCETAXEL; FAS LIGAND; GELATINASE A; GONADORELIN ANTAGONIST; JMR 132; LYMPHOTOXIN; UNCLASSIFIED DRUG;

ANGIOPOIETIN 1 GENE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CASPASE 14 GENE; CASPASE 4 GENE; CASPASE 5 GENE; CD70 GENE; CELL DEATH INDUCING DFFA LIKE EFFECTOR A GENE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEATH ASSOCIATED PROTEIN KINASE 1 GENE; FAS LIGAND GENE; FEMALE; GENE; GENE EXPRESSION; HARAKIRI GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MATRIX METALLOPROTEINASE 2 GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 10 GENE; TUMOR NECROSIS FACTOR SUPERFAMILY MEMBER 8 GENE; TUMOR XENOGRAFT; TWIST HOMOLOG 1 GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GROWTH HORMONE-RELEASING HORMONE; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; SERMORELIN; TAXOIDS; TRIPLE NEGATIVE BREAST NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84878177779     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2435     Document Type: Article

References (34)

1. Carey LA, Dees EC, Sawyer L, et al: The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007. (Pubitemid 46698581)
2. Dent R, Trudeau M, Pritchard KI, et al: Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13: 4429-4434, 2007. (Pubitemid 47219710)
3. Tischkowitz M, Brunet JS, Bégin LR, et al: Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 7: 134, 2007.
4. Schally AV, Steelman SL and Bowers CY: Effect of hypothalamic extracts on release of growth hormone in vitro. Proc Soc Exp Biol Med 119: 208-212, 1965.
5. Rick FG, Schally AV, Block NL, et al: Antagonists of growth hormone-releasing hormone (GHRH) reduce prostate size in experimental benign prostatic hyperplasia. Proc Natl Acad Sci USA 108: 3755-3760, 2011.
6. Kiaris H, Chatzistamou I, Papavassiliou AG and Schally AV: Growth hormone-releasing hormone: not only a neurohormone. Trends Endocrinol Metab 22: 311-317, 2011.
7. Rick FG, Szalontay L, Schally AV, et al: Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage. J Urol 187: 1498-1504, 2012.
8. Bagnato A, Moretti C, Ohnishi J, Frajese G and Catt KJ: Expression of the growth hormone-releasing hormone gene and its peptide product in the rat ovary. Endocrinology 130: 1097-1102, 1992.
9. Rick FG, Schally AV, Szalontay L, et al: Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc Natl Acad Sci USA 109: 1655-1660, 2012.
10. Busto R, Schally AV, Braczkowski R, et al: Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors. Regul Pept 108: 47-53, 2002. (Pubitemid 35239859)
11. Busto R, Schally AV, Varga JL, et al: The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 99: 11866-11871, 2002. (Pubitemid 34994490)
12. Chatzistamou I, Schally AV, Kiaris H, et al: Immunohistochemical detection of GHRH and its receptor splice variant 1 in primary human breast cancers. Eur J Endocrinol 151: 391-396, 2004. (Pubitemid 39307328)
13. Engel JB, Keller G, Schally AV, et al: Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 90: 3614-3621, 2005. (Pubitemid 41014334)
14. Frohman LA and Szabo M: Ectopic production of growth hormone-releasing factor by carcinoid and pancreatic islet tumors associated with acromegaly. Prog Clin Biol Res 74: 259-271, 1981.
15. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K and Busto R: The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 77: 15-26, 2003. (Pubitemid 36182913)
16. Guo J, Schally AV, Zarandi M, Varga J and Leung PC: Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod Biol Endocrinol 8: 54, 2010.
17. Kahán Z, Arencibia JM, Csernus VJ, et al: Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J Clin Endocrinol Metab 84: 582-589, 1999. (Pubitemid 29075688)
18. Schally A and Varga, JL: Antagonists of growth hormone-releasing hormone. Comb Chem High Throughput Screen 9: 163-170, 2006.
19. Schally AV, Comaru-Schally AM, Nagy A, et al: Hypothalamic hormones and cancer. Front Neuroendocrinol 22: 248-291, 2001. (Pubitemid 33010742)
20. Schally AV, Varga JL and Engel JB: Antagonists of growth-hormone- releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 4: 33-43, 2008. (Pubitemid 350291102)
21. Barabutis N, Siejka A, Schally AV, Block NL, Cai R and Varga L: Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor. J Mol Endocrinol 44: 127-134, 2010.
22. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A and Kiaris H: Stimulation of proliferation of MCF-7 breast cancer cells by a transfected splice variant of growth hormone-releasing hormone receptor. Proc Natl Acad Sci USA 104: 5575-5579, 2007. (Pubitemid 47175722)
23. Havt A, Schally AV, Halmos G, et al: The expression of the pituitary growth hormone-releasing hormone receptor and its splice variants in normal and neoplastic human tissues. Proc Natl Acad Sci USA 102: 17424-17429, 2005. (Pubitemid 41740882)
24. Rekasi Z, Czompoly T, Schally AV and Halmos G: Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 97: 10561-10566, 2000.
25. Köster F, Engel JB, Schally AV, et al: Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition. Breast Cancer Res Treat 116: 273-279, 2009.
26. Pombo CM, Zalvide J, Gaylinn BD and Dieguez C: Growth hormone-releasing hormone stimulates mitogen-activated protein kinase. Endocrinology 141: 2113-2119, 2000. (Pubitemid 32274364)
27. Siriwardana G, Bradford A, Coy D and Zeitler P: Autocrine/paracrine regulation of breast cancer cell proliferation by growth hormone releasing hormone via Ras, Raf, and mitogen-activated protein kinase. Mol Endocrinol 20: 2010-2019, 2006. (Pubitemid 44286701)
28. Berchem GJ, Bosseler M, Mine N and Avalosse B: Nanomolar range docetaxel treatment sensitizes MCF-7 cells to chemotherapy induced apoptosis, induces G2M arrest and phosphorylates bcl-2. Anticancer Res 19: 535-540, 1999. (Pubitemid 29168289)
29. Lavelle F, Bissery MC, Combeau C, Riou JF, Vrignaud P and André S: Preclinical evaluation of docetaxel (Taxotere). Semin Oncol 22: 3-16, 1995.
30. Buchholz S, Schally AV, Engel JB, et al: Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 104: 1943-1946, 2007. (Pubitemid 46239883)
31. Kovács M, Schally AV, Hohla F, et al: A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides 31: 1839-1846, 2010.
32. Rick FG, Schally AV, Block NL, et al: LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate 71: 736-747, 2011.
33. Umemura S, Yoshida S, Ohta Y, Naito K, Osamura RY and Tokuda Y: Increased phosphorylation of Akt in triple-negative breast cancers. Cancer Sci 98: 1889-1892, 2007. (Pubitemid 350002194)
34. Eralp Y, Derin D, Ozluk Y, et al: MAPK overexpression is associated with anthracycline resistance and increased risk for recurrence in patients with triple-negative breast cancer. Ann Oncol 19: 669-674, 2008. (Pubitemid 351461036)